ICSE China 2016, hosted by UBM EMEA and China Chamber of Commerce of Medicines & Health Products Importers & Exporters and co-organized by UBM Sinoexpo,will be held on 21 – 23rd June at Hall E2 in Shanghai New International Expo Centre, together with CPhI China.
As the global pharmaceutical product regulations become increasingly strict and pharmaceutical product’s R&D continues to become more demanding in recent years, in order to keep the profitability of pharmaceutical products in their entire life cycle, many transnational pharmaceutical enterprises have gradually turned their business model from “vertical integration” to “cooperation in development”. Decomposition of business links such as research, development and production of patented drugs, and outsourced them to pharmaceutical contract research organizations (CRO) and pharmaceutical contract manufacture organizations (CMO), etc. pharmaceutical contract service industry has formally entered the fast lane of development.
Reduction of drug R&D costs, growth of market share and increasing proportion of outsourcing have become an important means for transnational companies in developed countries to respond to market changes. China, as one of the most significant pharmerging markets, has been attracting more and more attention from Europe and America thanks to the virtue of inherent cost- effective advantage and gradually enhanced R&D production capabilities. ICSE China, as the exclusive CRO & CMO themed exhibition in China approved by the Ministry of Commerce of the P.R.C., is committed to create an international display platform for pharmaceutical contract service enterprises, and building a bridge for Chinese and overseas pharmaceutical enterprises and R&D institutions.
With the special advantage of CPhI global shows and constant increase of profile in China and overseas, ICSE China has become one of the important ways for Chinese contract pharmaceutical service enterprises to expand their overseas markets, and become much popular with new and regular exhibitors. CROs & CMOs including Porton ABA, UNICHEMIST, Chemspec, HaimenRuiyi, Granules-Biocause, Molbase, BSAZ, YWK Chemicals, Topharman, AccelaChemBio, Innovating, BONTAC and T&W, etc. have confirmed their continued participation, and will centrally showcase their latest technologies in fields such as custom synthesis, biotechnological clinical research, medicinal chemistry, registration and legislation associated services, process development/optimization, process scale-up production, API synthesis production, intermediate synthesis production and preparation production.
ICSE China will be co-located with BioPh China in the same hall of SNIEC, the two themed areas will focus on biological products and technologies, innovative products and quality brands among CROs & CMOs, and the discussion concerning industry dynamics and seeking of industry opportunities with industry professionals. The interaction of the two will also provide a convenient visiting channel for professionals in industries associated with pharmaceutical R&D, and provide buyers and enterprises with a R&D and/or procurement platform of unprecedented size and R&D solutions by gathering the numerous contract service and biopharmaceutical suppliers. In addition, Pharmaceutical R&D Innovation and Outsourcing Management Conference will be held during the show, offering visitors opportunitiesto find the best partners and obtain new ideas of constructing innovative partnership from the sharing of persons in charge of transnational pharmaceutical enterprises and Chinese innovative pharmaceutical enterprises.